Erika Hamilton: Fantastic list for ESMO Breast 24

Erika Hamilton shared a post by Paolo Tarantino on LinkedIn, adding:

“Fantastic list for ESMO Breast 24. Not only do we have some new drug data, but also data around practical questions such as: 1) rechallenging after G1 ILD to T-DXd, and 2) pregnancy after cancer for those w/ BRCA alterations!”

Quoting Paolo Tarantino’s post:

“Less than 48h to ESMO Breast 24: time for the top 10 abstracts.

Highly awaited readout from IMpassion132, safety update of important phase 3 trials (TROPION-Breast01, NATALEE), safety of T-DXd rechallenge after G1 ILD, intriguing biomarker analyses from large datasets (HER2DX, monarchE) and much more.

Promises to be a terrific congress!”

Source: Erika Hamilton/LinkedIn and Paolo Tarantino/LinkedIn

Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective.
OncoDaily
Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee a ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee. She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.